Indian nanocarrier silences two cancer-survival genes

ARI Pune scientists report a biodegradable nanoparticle that delivers gene-silencing RNA precisely to breast-tumour cells.

What happened

• Scientists at the Agharkar Research Institute (ARI), Pune reported a precision gene-silencing strategy against breast cancer.
• They engineered a biodegradable mesoporous silica nanoparticle that carries small interfering RNA (siRNA) into tumour cells.
• By coating it with a protamine biopolymer and an MUC1-specific aptamer, the carrier homes in on MUC1 receptors overexpressed on breast-cancer cells.
• It silences two anti-apoptotic genes — MCL-1 and Survivin — that help tumours survive and resist therapy.
• In MCF-7 cell models and SCID mice, it produced strong gene knockdown, more cancer-cell death and tumour-growth inhibition with minimal systemic toxicity; the work was published in Advanced Healthcare Materials.

For Prelims

• Who did it: the Agharkar Research Institute (ARI), Pune — an autonomous institute under the Department of Science & Technology (DST), Government of India. (Good to pair ARI with DST for an institution-matching question.)
• What RNA interference / siRNA is: small interfering RNA (siRNA) works through RNA interference — it binds a target messenger RNA and triggers its destruction, so the protein that mRNA codes for is never made. This 'silences' a gene at the mRNA level without altering the DNA.
• The delivery problem it solves: naked siRNA degrades fast and struggles to reach tumours, so it needs a carrier. Here the carrier is a biodegradable mesoporous silica nanoparticle — porous silica with high loading capacity and tunable surface chemistry.
• The targeting system: the surface carries a protamine biopolymer and an MUC1-specific aptamer (a short nucleic-acid 'address label'). MUC1 is a receptor overexpressed on breast-cancer cells, so the carrier preferentially binds tumour cells, improving uptake and reducing off-target effects.
• The two genes silenced: MCL-1 and Survivin are anti-apoptotic genes — they block apoptosis (programmed cell death), helping tumours survive and resist chemotherapy. Silencing both restores the cell's self-destruct pathway.
• Smart, stimulus-responsive release: the carrier is glutathione-responsive — it releases its siRNA payload inside the tumour microenvironment (where glutathione is high), concentrating the effect where it is needed.
• How it was tested: in MCF-7 breast-cancer cells and in SCID (Severe Combined Immunodeficiency) mice; results showed robust knockdown, increased apoptosis, tumour inhibition and low systemic toxicity on histology.
• What 'mesoporous' means: the silica particle is riddled with nanoscale pores (roughly 2–50 nm), giving a very high surface area that can load a large RNA/drug cargo.
• What an aptamer is: a short, folded DNA/RNA sequence that binds a specific molecular target — an antibody-like 'address label', here used to home in on the MUC1 receptor.
• The significance — precision oncology: the work combines targeted delivery + stimulus-responsive release + combinatorial gene silencing in one biodegradable platform — a template for safer RNAi-based cancer therapy versus broad-acting chemotherapy.

For Mains

Syllabus: GS3.13 · Linkage L2